Skip to main content

Chemotherapy

2
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
2
CamrelizumabPhase 2Monoclonal Antibody1 trial
Drug therapyPhase 21 trial
Active Trials
NCT05821452Not Yet Recruiting40Est. May 2026
NCT04635956Unknown20Est. Nov 2021
NeuroMetrix
NeuroMetrixMA - Woburn
1 program
Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic DrugsN/A1 trial
Active Trials
NCT01208545Unknown120
Ortho Development
1 program
Epoetin alfaPHASE_21 trial
Active Trials
NCT00337948Completed129Est. Feb 2005
Egetis Therapeutics
Egetis TherapeuticsSweden - Stockholm
1 program
MangafodipirPHASE_21 trial
Active Trials
NCT00671996Completed14Est. Apr 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNION therapeuticsCamrelizumab
UNION therapeuticsDrug therapy
Egetis TherapeuticsMangafodipir
Ortho DevelopmentEpoetin alfa
NeuroMetrixSerial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs

Clinical Trials (5)

Total enrollment: 323 patients across 5 trials

NCT05821452UNION therapeuticsCamrelizumab

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Start: May 2023Est. completion: May 202640 patients
Phase 2Not Yet Recruiting
NCT04635956UNION therapeuticsDrug therapy

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Start: Nov 2020Est. completion: Nov 202120 patients
Phase 2Unknown
NCT00671996Egetis TherapeuticsMangafodipir

Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C

Start: Jun 2008Est. completion: Apr 201014 patients
Phase 2Completed
NCT00337948Ortho DevelopmentEpoetin alfa

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Start: Feb 2003Est. completion: Feb 2005129 patients
Phase 2Completed
NCT01208545NeuroMetrixSerial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs

Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs

Start: Jul 2008120 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.